IP Library › Granted Patent US 11,596,650
Granted Patent B2
US 11,596,650 · App. 16/722,225 · Granted Mar 7, 2023

Composition and method for the treatment of type 2 diabetes

Inventors: Peter Novak (Sunny Isles Beach, FL); Maxim Temnikov (Miami, FL); Oleksandr Balakin (Dnepropetrovsk, UA)
Assignee: Vector Vitale IP LLC
A61K33/30A61K9/0019A61K9/0053A61P3/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,596,650
App. No.
16/722,225
Granted
Mar 7, 2023
Kind
B2
Abstract

A method of preventing or treating type 2 diabetes comprising administering a therapeutically effective amount of 64 Zn-enriched zinc.

Claims (11)

1. A method of treating type 2 diabetes in a subject in need thereof comprising administering to the subject a composition comprising a therapeutically effective amount of a 64 Zn e compound or a salt thereof, wherein the 64 Zn e compound or a salt thereof is at least 80% 64 Zn e , resulting in improved glucose metabolism in said subject.

2. The method of claim 1 , further comprising a diluent or an excipient.

3. The method of claim 2 , wherein the diluent is deuterium-depleted water.

4. The method of claim 1 , wherein the 64 Zn e compound or a salt thereof is at least 95% 64 Zn e .

5. The method of claim 1 , wherein the 64 Zn e compound or a salt thereof is at least 99% 64 Zn e .

6. The method of claim 1 , wherein the composition contains between 0.05 mg and 110 mg of 64 Zn e .

7. The method of claim 6 , wherein the composition contains between 1 and 10 mg of 64 Zn e .

8. The method of claim 1 , wherein the 64 Zn e compound or a salt thereof is at least 90% 64 Zn e and the composition is an aqueous solution in which 64 Zn e is present at a concentration of between 0.1 mg/ml and 10 mg/ml.

9. The method of claim 1 , wherein 64 Zn e is in a form of salt selected from the group consisting of zinc aspartate with 2 aspartic acid molecules, zinc sulfate, and zinc citrate, wherein the zinc aspartate has the structure

10. The method of claim 1 , wherein the composition is administered by injection.

11. The method of claim 1 , wherein the composition is administered orally.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2020
From: BALAKIN, OLEKSANDR
To: NOVAK, PETER Y.; TEMNIKOV, MAXIM V.
Reel/Frame 052686/0096 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2020
From: NOVAK, PETER Y.; TEMNIKOV, MAXIM V.
To: VECTOR VITALE IP LLC
Reel/Frame 052686/0185 →
Continuity (1)
Related Publication 20210187015A1 · Jun 24, 2021
Cited By (1)
US 12,734,240